₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

It's been a good week for Marksans Pharma Limited (NSE:MARKSANS) shareholders, because the company has just released its latest full-year results, and the shares gained 5.0% to ₹250. Results overall were respectable, with statutory earnings of ₹8.40 per share roughly in line with what the analysts had forecast. Revenues of ₹27b came in 3.0% ahead of analyst predictions. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the consensus forecast from Marksans Pharma's dual analysts is for revenues of ₹31.6b in 2026. This reflects a decent 17% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to surge 26% to ₹10.60. Before this earnings report, the analysts had been forecasting revenues of ₹30.4b and earnings per share (EPS) of ₹10.80 in 2026. There doesn't appear to have been a major change in sentiment following the results, other than the slight bump in revenue estimates.

See our latest analysis for Marksans Pharma

Even though revenue forecasts increased, the consensus price target 9.4% to ₹299, perhaps suggesting thatthe analysts have become more pessimistic about the lack of earnings growth.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Marksans Pharma'shistorical trends, as the 17% annualised revenue growth to the end of 2026 is roughly in line with the 16% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 10% annually. So although Marksans Pharma is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Marksans Pharma's future valuation.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have analyst estimates for Marksans Pharma going out as far as 2027, and you can see them free on our platform here.

Before you take the next step you should know about the 2 warning signs for Marksans Pharma (1 makes us a bit uncomfortable!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.